Back to top
more

KalVista Pharmaceuticals (KALV)

(Real Time Quote from BATS)

$10.18 USD

10.18
482,316

-0.17 (-1.64%)

Updated Apr 25, 2024 09:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for KALV

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

KalVista Pharmaceuticals, Inc. [KALV]

Reports for Purchase

Showing records 41 - 60 ( 105 total )

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 41

02/10/2021

Company Report

Pages: 8

KOL Feedback Affirms KVD900 Merit in HAE Attacks; PT to $48

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 42

01/21/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 43

01/20/2021

Company Report

Pages: 7

Quick Takeaways from Our Recent Call with Management

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 44

12/11/2020

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 45

12/11/2020

Company Report

Pages: 8

Two-Pronged Strategy for HAE Advances Forward, On-Demand Data Expected 1Q21

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 46

12/10/2020

Company Report

Pages: 6

FY 2Q21 Earnings Update - Phase 2 HAE Data Expected in 1Q21

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 47

10/16/2020

Daily Note

Pages: 5

KVD824 Visibility Fuels Impetus for Emerging Oral HAE Franchise; KVD900 Phase 2 Data Expected YE20

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 48

10/15/2020

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 49

10/15/2020

Daily Note

Pages: 6

Update Highlights Potential To Become Leading HAE Player. Reiterate Buy.

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 50

09/29/2020

Industry Report

Pages: 8

Key Takeaways From Week 1 of Our Talk Series

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 51

09/21/2020

Industry Report

Pages: 6

Register For Week-1 of Our Management Talk Series With IVA, RAPT, KALV - AGTC

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 52

09/15/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 53

09/15/2020

Company Report

Pages: 8

Fiscal Quarter Comes to a Close; With Approaching KVD900 HAE Data Expected 4Q20; Reit Buy and $30 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 54

09/15/2020

Industry Report

Pages: 6

Next Week We''ll Kick Off Our Management Talk Series

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 55

09/14/2020

Company Report

Pages: 6

FY 1Q21 Earnings Update - Two Major Value-Driving Catalysts During 4Q20

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 56

07/06/2020

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 57

07/02/2020

Company Report

Pages: 5

FY2020 Update - Timing of KVD900 and KVD824 Data Reaffirmed for 2H20

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 58

07/02/2020

Company Report

Pages: 8

Oral Kallikrein Inhibitor Progress on Horizon; On-Demand Phase 2 Data Anticipated 2H20

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 59

06/15/2020

Company Report

Pages: 59

Initiating With Buy and $30 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 100.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 60

04/17/2020

Industry Report

Pages: 4

COVID-19 Update: Cash Position - 2020 Catalysts of Covered Companies

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party